Pfizer Inc. (NYSE:PFE) Shares Sold by RWA Wealth Partners LLC

RWA Wealth Partners LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 59.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 272,798 shares of the biopharmaceutical company's stock after selling 393,531 shares during the quarter. RWA Wealth Partners LLC's holdings in Pfizer were worth $7,237,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. United Bank increased its stake in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after acquiring an additional 1,277 shares during the period. Fred Alger Management LLC lifted its holdings in shares of Pfizer by 7.4% in the 3rd quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company's stock valued at $2,971,000 after buying an additional 7,076 shares during the period. Tradition Wealth Management LLC raised its position in Pfizer by 4.5% during the third quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company's stock valued at $734,000 after acquiring an additional 1,099 shares in the last quarter. Bellevue Group AG increased its holdings in shares of Pfizer by 59.2% during the 3rd quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company's stock valued at $4,083,000 after purchasing an additional 52,461 shares in the last quarter. Finally, Semmax Financial Advisors Inc. lifted its stake in shares of Pfizer by 3.2% in the 3rd quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company's stock valued at $2,695,000 after purchasing an additional 3,185 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.06% of the company's stock.

Pfizer Trading Down 3.2 %

Shares of PFE traded down $0.82 during midday trading on Tuesday, reaching $24.53. The company had a trading volume of 54,333,514 shares, compared to its average volume of 39,155,820. The firm has a 50 day simple moving average of $26.05 and a 200-day simple moving average of $26.88. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $139.09 billion, a PE ratio of 17.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.